ArticleOrphanet journal of rare diseases2026
Clinical and genetic spectrum of dual rare genetic diseases revealed by whole-exome sequencing in 14 pediatric patients.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDual molecular diagnoses, defined as the coexistence of pathogenic variants in two distinct disease-causing genes, challenge the traditional single-gene model of Mendelian inheritance. With the advent of whole-exome sequencing (WES), such complex genotypes are increasingly recognized.
objectiveTo investigate the clinical and genetic spectrum of dual rare genetic diseases in pediatric patients and to assess the diagnostic utility of WES in detecting diverse variant types.
methodsA retrospective analysis was conducted on 872 children with suspected rare genetic disorders who underwent proband or trio-based WES from January 2019 to February 2025. Variants were classified according to American College of Medical Genetics and Genomics(ACMG) guidelines. Dual diagnoses were confirmed when two independent pathogenic or likely pathogenic variants, each explaining part of the phenotype, were identified.
resultsAmong 872 patients, 370 (42.4%) received a molecular diagnosis, and 14 (3.8%) were confirmed with dual molecular diagnoses. Autosomal dominant (AD) disorders were most frequent (85.7%), de novo variants represented 57.14% (8 out of 14 cases). Six patients (42.9%) harbored combinations of single nucleotide variant (SNV) and other variant types, including exon deletions, paternal uniparental disomy (UPD15). Clinically, 14.3% of cases were phenotypically distinct, while 85.7% were phenotypically overlapping.
conclusionDual molecular diagnoses occur in approximately 3.8% of molecularly diagnosed patients and frequently involve de novo dominant variants. WES effectively detects multiple variant types (including SNV, CNV, exon deletions, UPD, and mosaicism) providing crucial insights for precise diagnosis, management, and genetic counseling in children with complex phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.